Erydel puts Maxer in charge of the CTD/DT program for 2023-24

We are pleased to announce that EryDel S.p.A., now part of Quince Therapeutics Inc., has appointed Maxer Consulting to deliver its Clinical Trial Disclosure and Data Transparency program for 2023-24.

Maxer will carry out the activities necessary to ensure Erydel’s compliance with both the regulations in force in the European Union (EU Reg. 536/2014) and those of the United States (FDAAA 801 and Final Rule) to ensure the transparency of the results of clinical studies, including those that fall within the Expanded Access foreseen by the FDA.